Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Complete remission through blast cell differentiation inPLZF/RARα-positive acute promyelocytic leukemia: in vitro and in vivo studies

1 Aug 2002

Abstract excerpt

Acute leukemia with the t(11;17) expressing the PLZF-RARalpha gene fusion is a rare variant of acute promyelocytic leukemia (APL) that has been associated with poor clinical response to all-trans retinoic acid (ATRA) treatment. However, some recent reports have put into question the absolute refractoriness of this leukemia to ATRA. We describe here a patient with PLZF/RARalpha APL who was treated at relapse with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Antioxidant Activity and Oxidative Stress
Share to Retinoids in leukemia and cellular processes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 12130525
DOI: 10.1182/blood-2001-12-0368

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Complete remission through blast cell differentiation inPLZF/RARα-positive acute promyelocytic leukemia: in vitro and in vivo studiesPMID 12130525Read ↗

The Biology of Acute Promyelocytic Leukemia and Its Impact on Diagnosis and TreatmentSemantic proximity Read ↗

Revisiting the differentiation paradigm in acute promyelocytic leukemiaSemantic proximity Read ↗

Down-stream regions of the POZ-domain influence the interaction of the t(11;17)-associated PLZF/RARalpha fusion protein with the histone-deacetylase recruiting co-repressor complex.Semantic proximity Read ↗

The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease.Semantic proximity Read ↗

Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins on retinoic acid signalling.Semantic proximity Read ↗

Effects on differentiation by the promyelocytic leukemia PML/RARalpha protein depend on the fusion of the PML protein dimerization and RARalpha DNA binding domains.Semantic proximity Read ↗

The role of promyelocytic leukemia zinc finger and promyelocytic leukemia in leukemogenesis and developmentSemantic proximity Read ↗

Differentiation therapy of acute myeloid leukemia: past, present and futureSemantic proximity Read ↗

Classic and Variants APLs, as Viewed from a Therapy ResponseSemantic proximity Read ↗

Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARα fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patientSemantic proximity Read ↗

Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells.Semantic proximity Read ↗

Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.